Psyence Biomedical EBITDA Over Time
| PBMWW Stock | 0.01 0.0005 6.76% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Psyence Biomedical Performance and Psyence Biomedical Correlation. Psyence |
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Psyence Biomedical. If investors know Psyence will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Psyence Biomedical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Return On Assets (1.26) |
The market value of Psyence Biomedical is measured differently than its book value, which is the value of Psyence that is recorded on the company's balance sheet. Investors also form their own opinion of Psyence Biomedical's value that differs from its market value or its book value, called intrinsic value, which is Psyence Biomedical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Psyence Biomedical's market value can be influenced by many factors that don't directly affect Psyence Biomedical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Psyence Biomedical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Psyence Biomedical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Psyence Biomedical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Ebitda Analysis
Compare Psyence Biomedical and related stocks such as Viracta Therapeutics, Dogwood Therapeutics,, and Viking Therapeutics EBITDA Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VIRX | (25.1 M) | (19.8 M) | (42.1 M) | (31.7 M) | (41.3 M) | (35.7 M) | (36.3 M) | (34.1 M) | (25.5 M) | (12.1 M) | (18.8 M) | (114.1 M) | (50.4 M) | (46.9 M) | (49.2 M) |
| VKTX | (121.7 K) | (121.7 K) | (121.7 K) | (121.7 K) | (21.3 M) | (22.4 M) | (12.9 M) | (19.3 M) | (21.6 M) | (25.5 M) | 3.8 M | (55.4 M) | (70.4 M) | (100.8 M) | (95.8 M) |
| DYAI | (190.8 K) | 741.3 K | 741.3 K | 741.3 K | (4.9 M) | (5.8 M) | (5.3 M) | (12 M) | (7.6 M) | (9.2 M) | (10.2 M) | (13.1 M) | (10.1 M) | (8.2 M) | (8.6 M) |
| SRZNW | (22.8 M) | (22.8 M) | (22.8 M) | (22.8 M) | (22.8 M) | (22.8 M) | (22.8 M) | (22.8 M) | (22.8 M) | (22.8 M) | (31.4 M) | (52.3 M) | (42.4 M) | (41.1 M) | (43.2 M) |
| VNDA | (9.2 M) | (9.7 M) | (26.7 M) | (18.9 M) | (132.9 M) | (27.2 M) | (7.6 M) | (15.2 M) | 23.3 M | 24.3 M | 30.1 M | 45 M | 9.1 M | (14 M) | (14.6 M) |
| KTTAW | (41 K) | (41 K) | (41 K) | (41 K) | (41 K) | (41 K) | (41 K) | (41 K) | (41 K) | (41 K) | (41 K) | (4.5 M) | (12.6 M) | (15.3 M) | (14.6 M) |
| VRAX | (648.8 K) | (648.8 K) | (648.8 K) | (648.8 K) | (648.8 K) | (648.8 K) | (648.8 K) | (648.8 K) | (648.8 K) | (648.8 K) | (644.5 K) | (750) | (5.4 M) | (6.6 M) | (6.3 M) |
| VRCA | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (4.5 M) | (20.6 M) | (29.8 M) | (39.4 M) | (30.3 M) | (21.6 M) | (62.2 M) | (59.1 M) |
| VRDN | (3 M) | (3 M) | (3 M) | (297.9 K) | (6.8 M) | (11 M) | (9.5 M) | (26.1 M) | (31.8 M) | (41 M) | (109.7 M) | (78.8 M) | (128.6 M) | (234.6 M) | (222.8 M) |
Psyence Biomedical and related stocks such as Viracta Therapeutics, Dogwood Therapeutics,, and Viking Therapeutics Ebitda description
My Equities
My Current Equities and Potential Positions
| Psyence Biomedical Ltd | PBMWW |
Specialization | Healthcare, Biotechnology |
| Location | Ontario; Canada |
| Exchange | NASDAQ Exchange |
null 0.0069
Additional Tools for Psyence Stock Analysis
When running Psyence Biomedical's price analysis, check to measure Psyence Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Psyence Biomedical is operating at the current time. Most of Psyence Biomedical's value examination focuses on studying past and present price action to predict the probability of Psyence Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Psyence Biomedical's price. Additionally, you may evaluate how the addition of Psyence Biomedical to your portfolios can decrease your overall portfolio volatility.